EUVIMEDEUVIMED entdecken
Crossref

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) – single center experience after more than 100 procedures

E A Biesel, L Schäfer, C Berlin, G J Seifert, S Fichtner-Feigl, H P Neeff

Zeitschrift für Gastroenterologie · 01.08.2026 · 64 (08) · e576-e577

DOI: 10.1055/s-0046-1827007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.08.2026. Verfasst von E A Biesel und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is an innovative treatment approach for peritoneal carcinomatosis of different tumor origins in which a curatively intended cytoreductive surgery (CRS) is not possible. PIPAC has proven to be feasible and safe in former studies.

Aim

The aim of our study is the first evaluation of our PIPAC cohort concerning feasibility, complications and long-term survival after more than 100 procedures.

Methods

We launched our PIPAC program in October 2018 and included all patients scheduled for PIPAC therapy until March 2025 in our analysis. Our continuous data collection is carried out using a prospectively managed SPSS database. Primary outcome of our study was long-term overall survival following the first PIPAC procedure, secondary outcomes were postoperative complications and 30-day postoperative mortality.

Results

Between October 2018 and March 2025, altogether 127 procedures in 63 patients were scheduled for PIPAC therapy. Laparoscopic access was achieved in 102 cases (80.3%). Sixteen patients (25.4%) suffered from other distant organ metastases. Apart from postoperative nausea and vomiting, there were no relevant postoperative complications and no 30-day mortality. Concerning survival, we found a significant survival benefit in patients who were scheduled for cytoreductive surgery following PIPAC treatment (45.0 months (95% CI 34.2 – 55.8 months) vs. 14.0 months (95% CI 11.1 – 16.9 months), p=0.023).

Conclusion

In conclusion, PIPAC therapy is a safe surgical procedure, which is well tolerated by the majority of patients. Initially developed as a palliative treatment option accompanying the systemic chemotherapeutic treatment, it may be used as a kind of “neoadjuvant” treatment to enable CRS in selected cases. Publication History Article published online: 27 August 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Zitieren

APA

Biesel, E. A., Schäfer, L., Berlin, C., Seifert, G. J., Fichtner-Feigl, S., & Neeff, H. P. (2026). Pressurized intraperitoneal aerosol chemotherapy (PIPAC) – single center experience after more than 100 procedures. Zeitschrift für Gastroenterologie, 64(08), e576-e577. https://doi.org/10.1055/s-0046-1827007

Vancouver

Biesel EA, Schäfer L, Berlin C, Seifert GJ, Fichtner-Feigl S, Neeff HP. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) – single center experience after more than 100 procedures. Zeitschrift für Gastroenterologie. 2026;64(08):e576-e577. doi:10.1055/s-0046-1827007

BibTeX
@article{Biesel2026,
  author = {Biesel, E A and Schäfer, L and Berlin, C and Seifert, G J and Fichtner-Feigl, S and Neeff, H P},
  title = {Pressurized intraperitoneal aerosol chemotherapy (PIPAC) – single center experience after more than 100 procedures},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2026},
  volume = {64},
  number = {08},
  pages = {e576--e577},
  doi = {10.1055/s-0046-1827007}
}
Kostenlos starten →